JP2016508141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508141A5 JP2016508141A5 JP2015550799A JP2015550799A JP2016508141A5 JP 2016508141 A5 JP2016508141 A5 JP 2016508141A5 JP 2015550799 A JP2015550799 A JP 2015550799A JP 2015550799 A JP2015550799 A JP 2015550799A JP 2016508141 A5 JP2016508141 A5 JP 2016508141A5
- Authority
- JP
- Japan
- Prior art keywords
- transdermal
- dermatological composition
- active ingredient
- acid
- hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 32
- 239000004480 active ingredient Substances 0.000 claims 13
- 229940088597 hormone Drugs 0.000 claims 12
- 239000005556 hormone Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 239000003921 oil Substances 0.000 claims 9
- 235000019198 oils Nutrition 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 4
- 230000001153 anti-wrinkle effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000002337 glycosamines Chemical class 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims 3
- 240000000912 Macadamia tetraphylla Species 0.000 claims 3
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims 3
- 239000010466 nut oil Substances 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 150000001261 hydroxy acids Chemical class 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 claims 2
- 229960001669 kinetin Drugs 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 235000020944 retinol Nutrition 0.000 claims 2
- 239000011607 retinol Substances 0.000 claims 2
- MFSJSVNVUDQHLV-UHFFFAOYSA-N 2-(3-benzoylphenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFSJSVNVUDQHLV-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 241000208467 Macadamia Species 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 claims 1
- 229950008932 epolamine Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261748036P | 2012-12-31 | 2012-12-31 | |
| US61/748,036 | 2012-12-31 | ||
| US201361758726P | 2013-01-30 | 2013-01-30 | |
| US61/758,726 | 2013-01-30 | ||
| PCT/US2013/077985 WO2014106048A2 (en) | 2012-12-31 | 2013-12-27 | Liquid topical pharmaceutical nano-emulsion formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508141A JP2016508141A (ja) | 2016-03-17 |
| JP2016508141A5 true JP2016508141A5 (enExample) | 2017-02-09 |
| JP6403686B2 JP6403686B2 (ja) | 2018-10-10 |
Family
ID=51022202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550799A Active JP6403686B2 (ja) | 2012-12-31 | 2013-12-27 | 液体局所用医薬ナノエマルジョン製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150374835A1 (enExample) |
| EP (1) | EP2938324B1 (enExample) |
| JP (1) | JP6403686B2 (enExample) |
| KR (1) | KR20150102058A (enExample) |
| CN (2) | CN110201180A (enExample) |
| BR (1) | BR112015015788A2 (enExample) |
| EA (1) | EA201591015A1 (enExample) |
| ES (1) | ES2969933T3 (enExample) |
| SG (1) | SG11201505076UA (enExample) |
| WO (1) | WO2014106048A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| KR20180053318A (ko) * | 2015-09-17 | 2018-05-21 | 제이알엑스 바이오테크놀로지, 인코포레이티드 | 피부 수화 또는 보습을 향상시키기 위한 접근법 |
| WO2018063828A1 (en) | 2016-09-29 | 2018-04-05 | Jrx Biotechnology, Inc. | Methods and compositions for modifying plant growth and reducing water consumption by plants |
| PL3558269T3 (pl) | 2016-12-21 | 2024-11-18 | Dukebox Spółka Z Ograniczoną Odpowiedzialnością | Sposób wytwarzania emulsji woda w oleju nanocząsteczek paracetamolu |
| BR112020019592A2 (pt) * | 2018-03-28 | 2021-01-05 | Jrx Biotechnology, Inc. | Composições agrícolas |
| KR102117651B1 (ko) | 2018-04-27 | 2020-06-02 | 대구가톨릭대학교산학협력단 | 항산화, 주름개선 또는 염증개선용 한방 조성물 및 이를 포함하는 화장료 조성물 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374766A (en) | 1982-06-01 | 1983-02-22 | Charles Of The Ritz Group Ltd. | Combined allantoin-hydrolyzed animal protein product and method |
| US4973473A (en) | 1989-06-23 | 1990-11-27 | Revlon, Inc. | Skin care preparation |
| IT1232318B (it) | 1989-09-07 | 1992-01-28 | Crinos Industria Farmaco | Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo. |
| US5153174A (en) | 1989-10-30 | 1992-10-06 | Union Carbide Chemicals & Plastics Inc. | Polymer mixtures useful in skin care |
| CA2096242A1 (en) | 1990-11-14 | 1992-05-15 | Peter Ghosh | Anti-inflammatory composition derived from emu oil |
| US5297562A (en) | 1991-04-01 | 1994-03-29 | President And Fellows Of Harvard College | Method for detecting and treating Alzheimer's disease |
| IL101387A (en) | 1992-03-26 | 1999-11-30 | Pharmos Ltd | Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets |
| US5614212A (en) | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| US5318960A (en) | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
| KR940021073A (ko) | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i |
| US6113921A (en) * | 1993-03-23 | 2000-09-05 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
| US6103246A (en) | 1993-06-03 | 2000-08-15 | Tisdale; Carrie J. | Creams and lotions containing emu oil |
| US5840746A (en) | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US5472713A (en) | 1994-11-23 | 1995-12-05 | Elf Resources, Inc. | Therapeutic uses of emu oil |
| US5716625A (en) | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| US5744128A (en) | 1995-05-03 | 1998-04-28 | Holick; Michael F. | Use of emu oil for stimulating skin and hair growth |
| AUPN531195A0 (en) | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
| US5939082A (en) | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
| IT1289845B1 (it) | 1996-01-10 | 1998-10-16 | Guido Paduano | Formula per il trattamento della cute e suoi impieghi |
| US5891857A (en) | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
| EP0883433B1 (en) | 1996-03-01 | 2002-09-11 | Ebara Corporation | Desulfurizing method and apparatus by irradiation of electron beam |
| US5891651A (en) | 1996-03-29 | 1999-04-06 | Mayo Foundation For Medical Education And Research | Methods of recovering colorectal epithelial cells or fragments thereof from stool |
| US5861268A (en) | 1996-05-23 | 1999-01-19 | Biomide Investment Limited Partnership | Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase |
| US5708038A (en) | 1996-06-13 | 1998-01-13 | Univera Pharmaceuticals, Inc. | Method of using aloe vera as a biological vehicle |
| US5698227A (en) | 1996-07-23 | 1997-12-16 | Rivlin; Daniel | Compositions comprising lidocaine and emu oil and methods of use thereof |
| WO1998029085A2 (en) | 1996-12-31 | 1998-07-09 | American Medical Research, L.L.C. | Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties |
| AU6046198A (en) | 1997-01-31 | 1998-08-25 | Kenneth Hoyt | Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines |
| US5945446A (en) | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
| DK0999826T3 (da) | 1997-07-29 | 2004-07-26 | Upjohn Co | Selv-emulgerende formulering til lipofile forbindelser |
| US5885597A (en) | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
| ID25908A (id) | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| EP1075252A2 (en) | 1998-05-07 | 2001-02-14 | ELAN CORPORATION, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| TW537894B (en) * | 1998-05-26 | 2003-06-21 | Novartis Ag | A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist |
| DE69939019D1 (de) | 1998-07-07 | 2008-08-14 | Transdermal Technologies Inc | Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung |
| US7220427B2 (en) | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| WO2000002601A2 (en) | 1998-07-08 | 2000-01-20 | Oryxe | Transdermal delivery system |
| FR2787703B1 (fr) * | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| US20060121103A1 (en) | 2000-05-11 | 2006-06-08 | Kenneth Kirby | Transdermal delivery system |
| US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| AU2004283067A1 (en) | 2003-10-10 | 2005-05-06 | Oryxe | Transdermal high and low molecular weight compounds |
| DK1765310T3 (en) * | 2004-05-28 | 2016-01-11 | Oryxe | MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER |
| CA2566354C (en) | 2004-05-28 | 2016-01-12 | Oryxe | A mixture for transdermal delivery of low and high molecular weight compounds |
| US20050271752A1 (en) * | 2004-06-04 | 2005-12-08 | Roth Ivar E | Antifungal products and method of use |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| JP4974903B2 (ja) | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| US7371738B2 (en) * | 2005-04-15 | 2008-05-13 | University Of South Florida | Method of transdermal drug delivery using hyaluronic acid nanoparticles |
| US20070264346A1 (en) | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| CA2645080A1 (en) | 2006-03-07 | 2007-09-13 | Novavax,Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
| EP2170961A1 (de) * | 2007-07-25 | 2010-04-07 | S & V Technologies AG | Hyaluronsäuredispersion, herstellung und anwendung |
| GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
| DE102008034944B4 (de) * | 2008-07-26 | 2017-03-16 | Arivine Pharma Ag | Mikroemulsion |
| CN102389401B (zh) | 2011-11-22 | 2013-05-22 | 陆荣政 | 一种右旋布洛芬颗粒及其制备方法 |
-
2013
- 2013-12-27 CN CN201910440636.0A patent/CN110201180A/zh active Pending
- 2013-12-27 SG SG11201505076UA patent/SG11201505076UA/en unknown
- 2013-12-27 EP EP13869707.3A patent/EP2938324B1/en active Active
- 2013-12-27 JP JP2015550799A patent/JP6403686B2/ja active Active
- 2013-12-27 CN CN201380074085.1A patent/CN105209011B/zh active Active
- 2013-12-27 BR BR112015015788A patent/BR112015015788A2/pt not_active Application Discontinuation
- 2013-12-27 WO PCT/US2013/077985 patent/WO2014106048A2/en not_active Ceased
- 2013-12-27 KR KR1020157019652A patent/KR20150102058A/ko not_active Ceased
- 2013-12-27 ES ES13869707T patent/ES2969933T3/es active Active
- 2013-12-27 EA EA201591015A patent/EA201591015A1/ru unknown
- 2013-12-27 US US14/655,238 patent/US20150374835A1/en not_active Abandoned
-
2019
- 2019-09-18 US US16/575,056 patent/US12285487B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508141A5 (enExample) | ||
| Beckenbach et al. | Retinoid treatment of skin diseases | |
| JP6657394B2 (ja) | ざ瘡の予防および治療のためのタウリンおよびマグネシウムを含む局所用製剤および経口用製剤 | |
| JP2020143061A (ja) | 肥満の治療、重量増加の予防、重量減少の促進、スリミングの促進、又は糖尿病の進行の治療若しくは予防のための方法及び組成物 | |
| WO2014106048A3 (en) | Liquid topical pharmaceutical nano-emulsion formulations | |
| FR2903603A1 (fr) | Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne | |
| ME00828B (me) | Upotreba hitozana za lečenje inflamatornih oboljenja noktiju | |
| JP2010522146A5 (enExample) | ||
| JP2018522876A5 (enExample) | ||
| Webster et al. | A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne | |
| KR20120107864A (ko) | 피부병을 치료하기 위한 조성물, 상기 조성물을 함유하는 제제 및 그 제조 방법 | |
| EP3024450B1 (en) | Compositions and methods using tiglic aldehyde | |
| US20160114002A1 (en) | Compositions comprising plant proteins and methods for prevention of metabolic and cardiovascular pathologies in patient with cardiometabolic risk, including hyperglycemia | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| WO2012008457A1 (ja) | 外用組成物 | |
| EP3651755A1 (en) | Methods and compositions for the treatment of acne | |
| US11707469B2 (en) | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement | |
| CA2798420A1 (en) | Combination of an nsaid and an amino acid | |
| JP2019043865A (ja) | ざ瘡様疾患を治療又は予防するための皮膚外用組成物 | |
| JP2024518860A (ja) | 局所送達用組成物及び方法 | |
| JP4836044B2 (ja) | 経口アミノ酸ニキビ治療剤 | |
| JP2015000867A (ja) | 薬物内包粒子及びそれを含有する医薬製剤 | |
| AU2024285429A1 (en) | Transdermal delivery formulations | |
| Umekar et al. | Redefining acne treatment: emerging role of probiotics in dermatology | |
| XIAOFEI | Chinese Medica Market Attracts Global Players |